follow site Rayno Life Science Focus Stocks Are Strong-TMO Added
Biopharmaceutical stocks continue their run today beginning with higher sales expectations for Regeneron(REGN $128) with their eye drug for macular degeneration.Regeneron raised expectation for Eyelea to $700-750 from $500-550.Total revenue for Q2 was $304.4 with a profit up to $76.7M or 70 cents a share. The stock is up 5.77% as of mid-day trading but there is distribution of stock on a volume of 2.6M shares. Regeneron was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $17.5 a 7X return.
Another star in the Rayno Biopharmaceutical Portfolio is Alexion(ALXN $102.41) up 4.9% on a sales boost for Solaris to $274.7M compared to $185.7M in Q2 2011. Non-GAAP income was up 66% to $94.1M or 47 cents a share.
Other Rayno biopharmaceutical 2%+ movers today are Astex(ASTX $2.40), Biogen(BIIB $143), Cubist (CBST $41.48) and Optimer ($14.32). Biotech ETFs are up >1% IBB and XBI.
The tools and diagnostics sector shows some recovery from the Cepheid (CPHD) miss and we are looking for new ideas here. Our http://steps2stardom.com.au/uncategorized/online-pharmacy-dove-acquistare-levitra-oral-jelly/ top pick for the longer term is http://aspenlogandbeetlekillpinefurniture.com/2016/ Illumina(ILMN $42.3) up 2% today. Among the large cap integrated Tools/Dx companies ThermoFisher (TMO $53) is on a tear up 8% after raising estimates despite lower revenues .TMO is a good large cap value stock for a diversified life science portfolio. The Company is well managed and is moving aggressively into clinical diagnostics which is an excellent long term strategy.The forward PE is 9.3 with a P/S of 1.51.